Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial.
BACKGROUND
Three previous small randomized trials have reported that pacemaker therapy is beneficial for patients with severe recurrent vasovagal syncope. However, because these trials were not double blind, they may have been biased in their assessment of outcomes and had a placebo effect of surgery.


OBJECTIVE
To determine if pacing therapy reduces the risk of syncope in patients with vasovagal syncope.


METHODS
A randomized double-blind trial of pacemaker therapy in outpatients referred to syncope specialists at 15 centers from September 1998 to April 2002. In the year prior to randomization, patients had had a median of 4 episodes of syncope. Patients were followed up for up to 6 months.


METHODS
After implantation of a dual chamber pacemaker, 100 patients were randomly assigned to receive dual-chamber pacing (DDD) with rate drop response or to have only sensing without pacing (ODO).


METHODS
Time to first recurrence of syncope.


RESULTS
No patients were lost to follow-up. Of the 52 patients randomized to ODO, 22 (42%) had recurrent syncope within 6 months compared with 16 (33%) of 48 patients in the DDD group. The cumulative risk of syncope at 6 months was 40% (95% confidence interval [CI], 25%-52%) for the ODO group and 31% (95% CI, 17%-43%) for the DDD group. The relative risk reduction in time to syncope with DDD pacing was 30% (95% CI, -33% to 63%; 1-sided P =.14). Lead dislodgement or repositioning occurred in 7 patients. One patient had vein thrombosis, another had pericardial tamponade leading to removal of the pacemaker system, and a third had infection involving the pacemaker generator.


CONCLUSIONS
In this double-blind randomized trial, pacing therapy did not reduce the risk of recurrent syncope in patients with vasovagal syncope. Because of the weak evidence of efficacy of pacemaker therapy and the risk of complications, pacemaker therapy should not be recommended as first-line therapy for patients with recurrent vasovagal syncope.
Department of Medicine, McMaster University, Hamilton, Ontario. connostu@hhsc.ca
Stuart J
SJ
Connolly
Robert
R
Sheldon
Kevin E
KE
Thorpe
Robin S
RS
Roberts
Kenneth A
KA
Ellenbogen
Bruce L
BL
Wilkoff
Carlos
C
Morillo
Michael
M
Gent
D000328:Adult; D000368:Aged; D001919:Bradycardia / Q000150:complications / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial / Q000009:adverse effects; D016016:Proportional Hazards Models; D012008:Recurrence; D019462:Syncope, Vasovagal / Q000209:etiology / Q000517:prevention & control*